Artios Pharma secures USD84m in Series B financing
Artios Pharma Limited (Artios), a DNA Damage Response (DDR) company developing innovative treatments for cancer, has completed a USD84 million (GBP65 million) Series B financing following high interest from investors. The financing, which was significantly oversubscribed, was led by Andera Partners (formerly EdRIP) and LSP (Life Sciences Partners), with participation